Date Prepared: May 2013

CURRICULUM VITAE

NAME: Tatsuya Morimoto

OFFICE ADDRESS: 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan
Phone: +81(54) 264-5763
Fax: +81(54) 264-5744
E-mail: morimoto@u-shizuoka-ken.ac.jp

EDUCATION:

2000	Ph.D. Graduate School of Medicine, Kyoto University
1992	M.D. Faculty of Medicine, Kyoto University

ACADEMIC APPOINTMENT:

2009-present	Professor and chairman Division of Molecular Medicine, School of Pharmaceutical Sciences University of Shizuoka, Shizuoka, Japan
2007-2009	Chief Division of Translational Research Kyoto Medical Center, National Hospital Organization, Kyoto, Japan
2004-2007	Chief Laboratory of Molecular Cell Biology of Cardiovascular Disease Research Institute for Production Development, Kyoto, Japan
2000-2004	Postdoctoral Fellow Department of Cancer Biology Dana-Farber Cancer Institute, Harvard Medical School, USA

LICENSURE:

1992	Medical License of Japan

SOCIETY MEMBERSHIPS:

Japanese Circulation Society (Specialist)

Japanese Society of Internal Medicine (Specialist)

Japanese Heart Failure Society (Councilor)

International Society for Heart Research, Japanese Section (Councilor)

The Japanese Pharmacological Society (Councilor)

Japanese Society of Anti-Aging Medicine (Councilor)

The Pharmaceutical Society of Japan (Councilor, Editor)

The Society of Cardiovascular Endocrinology and Metabolism

Japanese Association of Cardiovascular Pharmacology

Japanese Society of Molecular Medicine

International Society of Cardiovascular Pharmacotherapy,
Japanese Section (Secretary)

Asian Pacific Society of Cardiology (Fellow)

American Heart Association

European Society of Cardiology (Councilor)

World Heart Federation (Board)

American Nano Society

American Society of Nephrology

Great Wall International Congress of Cardiology

PUBLICATIONS

1. Katanasaka Y, Sunagawa Y, Hasegawa K, Morimoto T. Application of curcumin to heart failure therapy by targeting transcriptional pathway in cardiomyocytes. ***Biol Pharm Bull. in press*** **(Corresponding author)**
2. Shimatsu A, Kakeya H, Imaizumi A, Morimoto T, Kanai M, Maeda S. Clinical Application of "Curcumin", a Multi-Functional Substance ***Anti-Aging Medicine*** 2012;9 (1):43-51. **(Corresponding author)**
3. Wada H, Ura S, Satoh-Asahara N, Kitaoka S, Mashiba S, Akao M, Abe M, Ono K, Morimoto T, Fujita M, Shimatsu A, Takahashi Y, Hasegawa K. α1-Antitrypsin Low-Density-Lipoprotein Serves as a Marker of Smoking-Specific Oxidative Stress. ***J Atheroscler Thromb*** 2012;19(1):47-58
4. Sunagawa Y, Wada H, Suzuki H, Sasaki H, Imaizumi A, Fukuda H, Hashimoto T, Katanasaka Y, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K, Morimoto T. A novel drug delivery system of oral curcumin markedly improves efficacy of treatment for heart failure after myocardial infarction in rat. ***Biol Pharm Bull.*** 2012;35(2):139-44. **(Corresponding author)**
5. Wada H, Ura S, Kitaoka S, Satoh-Asahara N, Horie H, Ono K, Takaya T, Takanabe-Mori R, Akao M, Abe M, Morimoto T, Murayama T, Yokode M, Fujita M, Shimatsu A, Hasegawa K. Distinct characteristics of circulating vascular endothelial growth factor-A and C levels in human subjects ***PLoS ONE*** 2011;6(12):e29351.
6.]Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya K, Fujita M, Hasegawa K, Morimoto T. Innovative preparation of curcumin for Improved oral bioavailability. ***Biol Pharm Bull.*** 2011;34(5):660-5. **(Corresponding author)**
7. Sunagawa Y, Morimoto T, Wada H, Takaya T, Katanasaka Y, Kawamura T, Yanagi S, Marui A, Sakata R, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K. A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin converting enzyme inhibitor exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. ***Circ J***. in press **(Corresponding author)**
8. Kaichi S, Takaya T, Morimoto T, Sunagawa Y, Kawamura T, Ono K, Shimatsu A, Baba S, Heike T, Nakahata T, Hasegawa K. Cyclin-dependent kinase 9 forms a complex with GATA4 and is involved in the differentiation of mouse ES cells into cardiomyocytes. ***J Cell Physiol.*** 2011;226(1):248-54.
9. Kaichi S, Hasegawa K, Morimoto T. Excessive apoptosis as a downstream molecular event during the development of congenital heart diseases. ***Circ J***. 2010;74(11):2297-8.
10. Fujita M, Sasayama S, Terasaki F, Mitani S, Morimoto T, Yamazaki T, Hayashi D, Kohro T, Okada Y, Nagai R; JCAD Study Investigators. Treatment effects of renin-angiotensin system inhibitor and calcium channel blocker in patients with coronary artery narrowing (from the Japanese Coronary Artery Disease Study). ***Heart Vessels***. 2010;25(6):453-9.
11. Kitamoto M, Kato K, Sugimoto A, Kitamura H, Uemura K, Takeda T, Wu C, Nogaki F, Morimoto T, Ono T. Sairei-to Ameliorates Rat Peritoneal Fibrosis Partly through

Suppression of Oxidative Stress. ***Nephron*** 2010;117(3):e71-e81.

12. Kaichi S, Hasegawa K, Takaya T, Yokoo N, Mima T, Kawamura T, Morimoto T, Ono K, Baba S, Yamanaka S, Nakahata T, Heike T. Cell line-dependent differentiation of induced pluripotent stem cells into cardiomyocytes in mice. ***Cardiovasc Res.*** 2010;88(2):314-23.
13. Sunagawa Y, Morimoto T, Takaya T, Wada H, Kawamura T, Fujita M, Shimatsu A, Kita T, Hasegawa K Cyclin-dependent kinsase-9 is a component of p300/GATA4 complex required for phenylephrine-induced hypertrophy in cardiomyocytes. ***J Biol Chem.*** 2010;285(13):9556-68. **(Corresponding author)**
14. Morimoto T, Sunagawa Y, Fujita M, Hasegawa K Novel heart failure therapy targeting transcriptional pathway in cardiomyocytes by a natural compound, curcumin. ***Circ J***. 2010;74(6):1059-66. **(Corresponding author)**
15. Takaya T, Wada H, Morimoto T, Sunagawa Y, Kawamura T, Takanabe-Mori R, Shimatsu A, Fujita Y, Sato Y, Fujita M, Kimura T, Sawamura T, Hasegawa K. Left Ventricular Expression of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 in Failing Rat Hearts. ***Circ J***. 2010 :25;74(4):723-9.
16. Wada H, Shinjo D, Kameda S, Ono K, Satoh N, Morimoto T, Osakada G, Nakano T, Fujita M, Shimatsu A, Hasegawa K Transmitral E/A ratio decreases in association with abdominal fat accumulation in patients with impaired glucose tolerance or mild diabetes without left ventricular hypertrophy. ***Heart Vessels.*** 2010;25(1):45-50.
17. Yoshida Y, Morimoto T, Takaya T, Kawamura T, Sunagawa Y, Wada H, Fujita M, Shimatsu A, Kita T, Hasegawa K Aldosterone Signaling Associates with p300/GATA4 Transcriptional Pathway during Hypertrophic Responses in Cardiomyocytes. ***Circ J***. 2010;74(1):156-62. **(Corresponding author)**
18. Wada H, Satoh N, Kitaoka S, Ono K, Morimoto T, Kawamura T, Nakano T, Fujita M, Kita T, Shimatsu A, Hasegawa K Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance. ***Atherosclerosis.*** 2010;208(2):512-517.
19. Takaya T, Ono K, Kawamura T, Takanabe R, Kaichi S, Morimoto T, Wada H, Kita T, Shimatsu A, Hasegawa K MicroRNA-1 and MicroRNA-133 in spontaneous myocardial differentiation of mouse embryonic stem cells. ***Circ J***. 2009;73(8):1397-8.
20. Wada H, Abe M, Ono K, Morimoto T, Kawamura T, Takaya T, Satoh N, Fujita M, Kita T, Shimatsu A, Hasegawa K. Statins activate GATA-6 and induce differentiated vascular smooth muscle cells. ***Biochem Biophys Res Commun.*** 2008;374(4):731-6.
21. Morimoto T, Fujita M, Kawamura K, Sunagawa Y, Takaya T, Wada H, Shimatsu A, Kita T, Hasegawa K Myocardial Regulation of p300 and p53 by Doxorubicin Involves Ubiquitin Pathways. ***Circ J***. 2008;72(9):1506-11. **(Corresponding author)**
22. Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, Nagasawa A, Komeda M, Fujita M, Shimatsu A, Kita T, Hasegawa K: The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. ***J Clin Invest.*** 2008;118:868-78
23. Takaya T, Kawamura T, Morimoto T, Ono K, Kita T, Shimatsu A, Hasegawa K. Identification of p300-targeted acetylated residues in GATA-4 during hypertrophic responses in cardiac myocytes. ***J Biol Chem.*** 2008;283(15):9828-35
24. Wada H, Hasegawa K, Terashima S, Satoh N, Inoue M, Iida Y, Yamakage H, Kitaoka S, Morimoto T, Fujita M, Shimatsu A, Takahashi Y. Knowledge and interest

regarding smoking-related health risks in smokers and non-smokers. Self-rating depression scale score is a strong independent predictor of smoking cessation outcomes ***Smoking Control Science*** 2008; 4: 4-8

25. Hosseinkhani M, Hasegawa K, Ono K, Kawamura T, Takaya T, Morimoto T, Wada H, Shimatsu A, Prat SG, Suemori H, Nakatsuji N, Kita T. Trichostatin A induces myocardial differentiation of monkey ES cells ***Biochem Biophys Res Commun***. 2007;356(2):386-91.
26. Fujita M, Morimoto T, Ikemoto M, Takeda M, Ikai A, Miwa K: Dose-dependency in pleiotropic effects of atorvastatin. ***Int J Angiol.*** 2007;16(3):89-91
27. Miyamoto S, Kawamura T, Morimoto T, Ono K, Kawase Y, Kita T, Hasegawa K Histone acetyltransferase activity of p300 is required for the promotion of left ventricular remodeling following myocardial infarction in adult mice in vivo ***Circulation***. 2006;113(5):679-90
28. Kawamura T, Ono K, Morimoto T, Wada H, Hirai M, Hidaka K, Morisaki T, Heike T, Nakahata T, Kita T, Hasegawa K. Acetylation of GATA-4 is involved in the differentiation of embryonic stem cells into cardiac myocytes. ***J Biol Chem.*** 2005;280(20):19682-8
29. Ehara N, Ono K, Morimoto T, Kawamura T, Abe M, Hasegawa K. The possible role of peroxisome proliferator-activated receptor gamma in heart failure. ***Exp Clin Cardiol***. 9:169-173, 2004
30. Kawamura T, Hasegawa K, Morimoto T, Iwakura A, Nishina T, Nomoto T, Komeda M. Down-regulation of Endothelin-1 and alteration of apoptosis signaling following left ventricular volume reduction surgery in heart failure of adult rats***. J Cardiovasc Pharmacol***. 2004;44 Suppl 1:S366-71.
31. Ehara N, Hasegawa K, Ono K, Kawamura T, Iwai-Kanai E, Morimoto T, Akao M, Adachi S, Kita T Activators of PPARgamma antagonize protection of cardiac myocytes by endothelin-1 ***Biochem Biophys Res Commun***. 2004;321(2):345-9
32. Hirai M, Ono K, Morimoto T, Kawamura T, Wada H, Kita T, Hasegawa K FOG-2 competes with GATA-4 for a transcriptional coactivator p300 and represses hypertrophic responses in cardiac myocytes. ***J Biol Chem.*** 2004;279(36):37640-50
33. Kawamura T, Ono K, Morimoto T, Akao M, Iwai-Kanai E, Wada H, Sowa N, Kita T, Hasegawa K Endothelin-1-dependent nuclear factor of activated T lymphocyte signaling associates with transcriptional coactivator p300 in the activation of the B cell leukemia-2 promoter in cardiac myocytes. ***Circ Res***. 2004;94(11):1492-9
34. Kawamura T, Hasegawa K, Morimoto T, Iwai-Kanai E, Miyamoto S, Kawase Y, Ono K, Wada H, Akao M, Kita T Expression of p300 protects cardiac myocytes from apoptosis in vivo. ***Biochem Biophys Res Commun***. 2004;315(3):733-8
35. Yanazume T, Morimoto T, Wada H, Kawamura T, Hasegawa K Biological role of p300 in cardiac myocytes. ***Mol Cell Biochem***. 2003;248(1-2):115-9.
36. Yanazume T#, Hasegawa K, Morimoto T#, Kawamura T#, Wada H, Matsumori A, Kawase Y, Hirai M, Kita T. Cardiac p300 is involved in myocyte growth with decompensated heart failure. ***Mol Cell Biol.*** 2003;23(10):3593-606. (#:equal contributor)
37. Abe M, Hasegawa K, Wada H, Morimoto T, Yanazume T, Kawamura T, Hirai M, Furukawa Y, Kita T. GATA-6 is involved in PPARgamma-mediated activation of differentiated phenotype in human vascular smooth muscle cells. ***Arterioscler Thromb Vasc Biol.*** 2003;23(3):404-10.

38. Wada H, Hasegawa K, Morimoto T, Kakita T, Yanazume T, Abe M, Sasayama S. Calcineurin-GATA-6 pathway is involved in smooth muscle-specific transcription. ***J Cell Biol.*** 2002;156(6):983-91.
39. Yanazume T, Hasegawa K, Wada H, Morimoto T, Abe M, Kawamura T, Sasayama S. Rho/ROCK pathway contributes to the activation of extracellular signal-regulated kinase/GATA-4 during myocardial cell hypertrophy. ***J Biol Chem*** **.** 2002;277(10):8618-25.
40. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Wada H, Yanazume T, Sasayama S: Calcineurin-GATA4 pathway is involved in β-adrenergic agonist-responsive endothelin-1 transcription in cardiac myocytes. ***J Biol Chem.*** 2001**.**;276(37):34983-9.
41. Kakita T, Hasegawa K, Iwai-Kanai E,Adachi S, Morimoto T, Wada H, Kawamura T,Yanazume T, Sasayama S. Calcineurin pathway is required for endothelin-1-mediated protection against oxidant stress-induced apoptosis in cardiac myocytes. ***Circ Res.*** 2001;88(12):1239-46.
42. Araki M, Hasegawa K, Iwai-Kanai E, Fujita M, Sawamura T, Kakita T, Wada H, Morimoto T, Sasayama S. Endothelin-1 as a protective factor against beta-adrenergic agonist-induced apoptosis in cardiac myocytes. ***J Am Coll Cardiol***. 2000;36(4):1411-8.
43. Wada H, Hasegawa K, Morimoto T, Kakita T, Yanazume T, Sasayama S: A p300 Protein as a Coactivator of GATA-6 in the Transcription of Smooth Muscle-Myosin Heavy Chain Gene. ***J Biol Chem*****.** 2000;275(33):25330-5.
44. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Wada H,Yanazume T,Sasayama S: Phosphorylation of GATA-4 is involved in α1-adrenergic agonist-responsive transcription of the Endothelin-1 gene in cardiac myocytes. ***J Biol Chem.***2000 :275: 13721-6
45. Kakita T, Hasegawa K, Morimoto T, Kaburagi S, Wada H, Sasayama S. p300 protein as a coactivator of GATA-5 in the transcription of cardiac-restricted atrial natriuretic factor gene. ***J Biol Chem.***1999 :274:34096-102.
46. Iwai-Kanai E, Hasegawa K, Araki M, Kakita T, Morimoto T, Sasayama S. alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. ***Circulation***. 1999;100(3):305-11.
47. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Masutani H, Kitsis RN, Matsumori A, Sasayama S. GATA-5 is involved in leukemia inhibitory factor-responsive transcription of the β-myosin heavy chain gene in cardiac myocytes. ***J Biol Chem.*** 1999;274:12811-8.
48. Kaburagi S, Hasegawa K, Morimoto T, Araki M, Sawamura T, Masaki T, Sasayama S. The role of endothelin-converting enzyme-1 in the development of alpha1-adrenergic-stimulated hypertrophy in cultured neonatal rat cardiac myocytes. ***Circulation***. 1999;99(2):292-8.
49. Shiota T, Arizono N, Morimoto T, Shimatsu A, Nakao K. Trichomonas tenax empyema in an immunocompromised patient with advanced cancer. ***Parasite***. 1998;5(4):375-7.